letters to the editor

- 7. Wyatt CM, Klotman PE. HIV-associated nephropathy in the era of antiretroviral therapy. *Am J Med* 2007; 120 (6): 488-92.
- Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. *Am J Kidney Dis* 1996; 28 (2): 202-8.

R. Valero, E. Rodrigo, C. Piñera and M. Arias

Servicio de Nefrología. Hospital Universitario Marqués de Valdecilla.

Correspondence: Rosalía Valero San Cecilio. rosaliavalero@yahoo.es. FRIAT. Centro de Diálisis Los Llanos. C/ Fragata, 21. 28222 Majadahonda. Madrid. España.

Psychotropic drugs and peritoneal dialysis

Nefrología 2008; 28 (5) 656

To the editor: Patient acceptance of chronic disease often involves adjustment problems and thus anxiety-depressive disorders in reaction to the new situation. These problems in turn can be aggravated by situations of physical dependency typically found in patients suffering from multiple disease processes.

Patients with chronic kidney disease subjected to dialysis moreover often experience insomnia, which reduces their quality of life and increases the mortality risk.¹ Restless legs syndrome is common in uremic patients, and worsens at night – preventing adequate sleep and constituting a mortality risk factor.² On the other hand, it is known that worsened quality of sleep during the first year on dialysis is associated with a shortened life expectancy.³

The use of benzodiazepines, which are the most widely used drugs for treating anxiety, is common in patients on dialysis. Their use is associated with important patient mortality.⁴⁻⁵

The present study analyzes physical dependency, comorbidity, the frequency of anxiety-depressive disorders, and sleep disturbances, as well as psychotropic drug consumption (benzodiazepines, non-benzodiazepinic hypnotics and antidepressants) among all patients in our Peritoneal dialysis Unit. To this effect, we analyzed all our patients included in the peritoneal dialysis program of our Unit, with determination of the Barthel index (dependency scale for basic daily life activities), the Charlson-Bedhu comorbidity scale, and the Hamilton anxiety-depression scale. Prescribed treatment was reviewed to determine psychotropic drug consumption frequency.

There were 10 patients with a mean age of 56 ± 16 years (range 33-77). The mean duration of enrollment in the peritoneal dialysis program was 12.85 ± 12.14 months (range 1-36). Forty percent of the patients were on ambulatory continuous peritoneal dialysis and 60% on automated peritoneal dialysis. The mean modified Charlson comorbidity score was 5.5 ± 2.14 (range 4-11). According to the Barthel index, 10% of the patients showed severe dependency (35 points), 20% mild dependency (75 and 85 points), and the rest (70%) no dependency (100 points). The Hamilton anxiety-depression scale in turn indicated that 20% of the patients suffered anxiety (> 8 points), while 10% scored in the depression range (> 18 points). As regards insomnia, 50% had no sleeping difficulties. The remaining 50% tended to wake up at night, and 30% were unable to fall sleep again afterwards. Psychoactive drug consumption showed two patients to use benzodiazepines, one consumed zolpidem, one used antidepressants, and another antidepressants and benzodiazepines.

It can be concluded that our patient population suffered medium-high morbidity. Most of the patients (70%) were independent for activities of daily living. Thirty percent of our patients suffered some anxiety-depressive disorder. Insomnia was found to be very common (50%). Finally, psychotropic drug use was quite common - 50% of our patients being shown to use some drug of this kind.

- 2. Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. *Am J Kidney Dis* 2004; 43 (5): 763-71.
- Unruh ML, Buysse DJ, Dew MA, Evans IV, Wu AW, Fink NE, Powe NR, Meyer KB. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Sleep quality and its correlates in the first year of dialysis. *Clin J Am Soc Nephrol* 2006; 1 (4): 802-10.
- Winkelmayer WC, Mehta J, Wang PS. Benzodiazepine use and mortality of incident dialysis patients in the United Status. *Kidney Int* 2007; 72 (11): 1388-93.
- Fukuhara S, Green J, Albert J, Mihara H, Pisoni R, Yamazaki s, Akiba T, Asano Y, Saito A, Port F, Held P, Kurokawa K. Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan. *Kidney Int* 2006; 70 (10): 1866-72.

A. Sastre López, M. R. Bernabéu Lafuente, M. V. Íñigo Vanrell and J. M. Gascó Company

Servicio de Nefrología. Hospital Son Llátzer. Palma de Mallorca.

Correspondence: Aránzazu Sastre López. aranchasastre@hotmail.com. HUCA. Avda. Fernández Ladreda, 30. 24005 León. España.

Topiramate-induced renal tubular acidosis. A case report

Nefrología 2008; 28 (6) 656-657

To the editor: Topiramate is an antiepileptic drug also used to treat bipolar disorder, neuropathic pain and migraine. The potential side effects of the drug include metabolic acidosis due to renal bicarbonate loss and the accumulation of CO_2 in the brain, as a result of its inhibitory action upon carbonic anhydrase (renal and located in the microglia, myelin and choroid plexus).

We report the case of a 58-year-old male with a history of absence-type epilepsy subjected to treatment with topiramate (150 mg/day) for the past 10 years. He also presented chronic renal failure (CKF) not subjected to evaluation and with baseline serum creatinine 2 mg/dl, hypersomnolence under study, and pulmonary thromboembolism (PTE) secondary to deep venous thrombosis (DVT) in the right leg due to trauma, in 1981. The patient was admitted to the Service of Pneumology diagnosed with bilateral PTE associated to DVT. The Service of Nephrology was consulted due to the sustained presence of acidosis.

Elder SJ, Pisoni RL, Akizawa T, Fissell R, Andreucci VE, Fukuhara S, Kurokawa K, Rayner HC, Furniss AL, Port FK, Saran R. Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2008; 23 (3): 998-1004.